deferoxamine has been researched along with Diathesis in 14 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The iron chelator, deferoxamine (DFO), has been shown to potentially improve dermal radiation-induced fibrosis (RIF) in mice through increased angiogenesis and reduced oxidative damage." | 8.02 | A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis. ( Abbas, DB; Chen, K; Diaz Deleon, NM; Fahy, EJ; Griffin, M; Gurtner, GC; Lavin, CV; Lee, DK; Longaker, MT; Mascharak, S; Momeni, A; Wan, DC, 2021) |
| "The iron chelator, deferoxamine (DFO), has been shown to potentially improve dermal radiation-induced fibrosis (RIF) in mice through increased angiogenesis and reduced oxidative damage." | 4.02 | A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis. ( Abbas, DB; Chen, K; Diaz Deleon, NM; Fahy, EJ; Griffin, M; Gurtner, GC; Lavin, CV; Lee, DK; Longaker, MT; Mascharak, S; Momeni, A; Wan, DC, 2021) |
| "The effect of the iron chelator deferoxamine (DFO) on resistance to infection with Listeria monocytogenes in mice with a condition analogous to human beta-thalassemia was studied." | 3.68 | Deferoxamine increases the susceptibility of beta-thalassemic, iron-overloaded mice to infection with Listeria monocytogenes. ( Ampel, NM; Bejarano, GC; Saavedra, M, 1992) |
| " The severe toxic effects on vision, hearing and growth are all more likely at higher doses of DF and there appears to be partial protection against them by iron overload." | 2.38 | The toxic effects of desferrioxamine. ( Huehns, ER; Porter, JB, 1989) |
| "Pancytopenia is difficult to manage in patients with this disorder." | 1.32 | Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin. ( Erduran, E; Hacisalihoglu, S; Ozoran, Y, 2003) |
| " Our results demonstrate the importance of haemosiderosis in the increased susceptibility of haemodialysed patients to infections; this susceptibility is decreased by desferrioxamine therapy, which probably acts by restoring phagocytosis and reducing the bioavailability of iron for pathogens." | 1.28 | Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. ( Collart, FE; Dratwa, M; Lenclud, CM; Tielemans, CL; Wens, R, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Lavin, CV | 1 |
| Abbas, DB | 1 |
| Fahy, EJ | 1 |
| Lee, DK | 1 |
| Griffin, M | 1 |
| Diaz Deleon, NM | 1 |
| Mascharak, S | 1 |
| Chen, K | 1 |
| Momeni, A | 1 |
| Gurtner, GC | 1 |
| Longaker, MT | 1 |
| Wan, DC | 1 |
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 1 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Cinque, P | 1 |
| Casale, M | 1 |
| Filosa, A | 1 |
| Prossomariti, L | 1 |
| Erduran, E | 1 |
| Hacisalihoglu, S | 1 |
| Ozoran, Y | 1 |
| Boelaert, JR | 2 |
| Blei, F | 1 |
| Puder, DR | 1 |
| Mencacci, A | 1 |
| Cenci, E | 1 |
| Bucci, P | 1 |
| Mosci, P | 1 |
| Fè d'Ostiani, C | 1 |
| Bistoni, F | 1 |
| Romani, L | 1 |
| Ghosh, K | 1 |
| Daar, S | 1 |
| Hiwase, D | 1 |
| Nursat, N | 1 |
| Prati, D | 1 |
| Ampel, NM | 1 |
| Bejarano, GC | 1 |
| Saavedra, M | 1 |
| Anand, VK | 1 |
| Alemar, G | 1 |
| Griswold, JA | 1 |
| Tielemans, CL | 1 |
| Lenclud, CM | 1 |
| Wens, R | 1 |
| Collart, FE | 1 |
| Dratwa, M | 1 |
| Porter, JB | 1 |
| Huehns, ER | 1 |
| Hershko, C | 1 |
| Peto, TE | 1 |
| Weatherall, DJ | 1 |
| van der Kraaij, AM | 1 |
| Mostert, LJ | 1 |
| van Eijk, HG | 1 |
| Koster, JF | 1 |
6 reviews available for deferoxamine and Diathesis
| Article | Year |
|---|---|
Mucormycosis (zygomycosis): is there news for the clinician?
Topics: AIDS-Related Opportunistic Infections; Deferoxamine; Disease Susceptibility; Drug Therapy; Humans; M | 1994 |
Yersinia enterocolitica bacteremia in a chronically transfused patient with sickle cell anemia. Case report and review of the literature.
Topics: Adolescent; Anemia, Sickle Cell; Bacteremia; Blood Transfusion; Ceftriaxone; Deferoxamine; Disease S | 1993 |
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major.
Topics: Anemia, Hemolytic; beta-Thalassemia; Blood Group Incompatibility; Blood Transfusion; Cardiovascular | 2000 |
Intracranial complications of mucormycosis: an experimental model and clinical review.
Topics: Adult; Alloxan; Amphotericin B; Animals; Brain Abscess; Brain Diseases; Child; Deferoxamine; Diabete | 1992 |
The toxic effects of desferrioxamine.
Topics: Animals; Blood-Brain Barrier; Deferoxamine; Disease Susceptibility; Eye Diseases; Growth Disorders; | 1989 |
Iron and infection.
Topics: Adult; Bacteria; Bacterial Infections; Deferoxamine; Disease Susceptibility; Humans; Infant; Infant, | 1988 |
8 other studies available for deferoxamine and Diathesis
| Article | Year |
|---|---|
A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis.
Topics: Animals; Biomarkers; Deferoxamine; Dermis; Disease Susceptibility; Female; Fibrosis; Mice; Microvess | 2021 |
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Sus | 2014 |
Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin.
Topics: Blood Cell Count; Bone Marrow; Child, Preschool; Deferoxamine; Disease Susceptibility; Dyskeratosis | 2003 |
Iron overload alters innate and T helper cell responses to Candida albicans in mice.
Topics: Animals; Candida albicans; Candidiasis; Cytokines; Deferoxamine; Disease Susceptibility; Ferric Comp | 1997 |
Primary pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Blood Transfusion; Chelating Agents; Chelation Therapy; C | 2000 |
Deferoxamine increases the susceptibility of beta-thalassemic, iron-overloaded mice to infection with Listeria monocytogenes.
Topics: Animals; Colony Count, Microbial; Deferoxamine; Disease Susceptibility; Female; Injections, Intraper | 1992 |
Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine.
Topics: Aluminum; Bacterial Infections; Deferoxamine; Disease Susceptibility; Ferritins; Humans; Iron; Renal | 1989 |
Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine.
Topics: Animals; Antioxidants; Cardiomyopathies; Catechin; Coronary Circulation; Deferoxamine; Disease Susce | 1988 |